Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after undruggable targets in cancer.
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission.
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say.
Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity.
Sofinnova Partners aims to invest in 50 to 60 new companies in the life sciences. The infusion of new capital brings the VC firm’s assets under management to more than €4 billion.
Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health. Accepted applicants will be admitted to Altitude Lab, the Salt Lake City biotech accelerator formed by Recursion Pharmaceuticals.
Radiologists today face a surge in imaging volume and pressure to produce fast, accurate reports. Workflow optimization is about delivering the right results at the right time with less friction.
This year, venture capitalists in the digital health landscape have many more quality investment opportunities than they did in the past couple years, according to Oak HC/FT Partner Billy Deitch. He noted that many startups have been preserving the capital over the past two years with the plan to raise funds in 2025.
China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is booming as well as therapeutic areas where he sees promising science.
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
Applications of SandboxAQ’s large quantitative models (LQMs) technology include running simulations that identify new biomarkers and optimize clinical development of drug candidates. The company spun out of Alphabet in 2022.
The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions.
Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington professor of biochemistry recently awarded the Nobel Prize in Chemistry for his work in computational protein design.
Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent's lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck's blockbuster med Keytruda in a pivotal head-to-head study.
Seaport Therapeutics’ Series B financing was one of the largest rounds of funding in our recap of biotech financing news, which spans startups developing drugs for neurological diseases, cancer, immunology, and more.